All In Biotech

NDA 208083 · Baxter Hlthcare Corp

Clindamycin Phosphate In 0.9% Sodium Chloride

Clindamycin Phosphate · Intravenous

Last checked: Nov 20, 2026Latest source record: Sep 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 20, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

3,562

2,260 serious, 264 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) and COLITIS Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Clindamycin Phosphate in Sodium Chloride Injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because Clindamycin Phosphate in Sodium Chloride Injection therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate [ see Indications and Usage ( 1 ) ] . It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin...

What it is approved for

From the label in effect Apr 28, 2026.

Clindamycin Phosphate in Sodium Chloride Injection contains clindamycin, a lincosamide antibacterial indicated for the treatment of the following in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: • Serious infections caused by susceptible anaerobic bacteria ( 1.1 ) • Infections Due to Susceptible Isolates of Streptococci, Pneumococci and Staphylococci. ( 1.2 ) • Lower Respiratory Tract Infections. ( 1.3 ) • Skin and Skin Structure Infections. ( 1.4 ) • Gynecological Infections. ( 1.5 ) • Intra-abdominal Infections. ( 1.6 ) • Septicemia. ( 1.7 ) • Bone and Joint Infections. ( 1.8 ) Limitation of use Since clindamycin does not diffuse adequately into the cerebrospinal fluid, Clindamycin Phosphate in Sodium Chloride Injection should not be used in the treatment of meningitis ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Phosphate in Sodium Chloride Injection and other antibacterial drugs, Clindamycin Phosphate in Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.10 ) 1.1 Infections Due to Susceptible Anaerobic Bacteria Clindamycin Phosphate in Sodium Chloride Injection is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Indications and Usage (1.3 - 1.7) ] . 1.2 Infections Due to Susceptible Isolates of Streptococci, Pneumococci and Staphylococci Clindamycin Phosphate in Sodium Chloride Injection is indicated for the treatment of serious infections due to susceptible isolates of streptococci, pneumococci, and...

Mechanism: Clindamycin is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 20, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
  • CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE · CLINDAMYCIN PHOSPHATE EQ 900MG BASE/50ML (EQ 18MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE · CLINDAMYCIN PHOSPHATE EQ 300MG BASE/50ML (EQ 6MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE · CLINDAMYCIN PHOSPHATE EQ 600MG BASE/50ML (EQ 12MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective373
  • rash257
  • drug hypersensitivity230
  • off label use227
  • diarrhoea190
  • nausea186
  • fatigue169
  • pruritus168
  • pain161
  • condition aggravated135
  • dyspnoea114
  • headache113

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200548
200656
200714
200820
200943
201082
201165
201295
2013101
2014102
2015124
2016242
2017182
2018237
2019276
2020210
2021194
2022288
2023305
2024286
2025309
2026264

Recalls

1 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

  • Current · updated Nov 3, 2026

    Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50). Other

  • Current · updated Nov 18, 2026

    Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50).

  • Current · updated Nov 18, 2026

    Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,207 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.